Literature DB >> 1424211

Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone.

J N Bradbeer1, M E Arlot, P J Meunier, J Reeve.   

Abstract

OBJECTIVE: We wished to determine whether treatment of vertebral osteoporosis with human parathyroid peptide 1-34 (hPTH 1-34), given as a daily injection with supplementary treatment with hormone replacement therapy (HRT), increases cancellous bone area in the ilium by increasing the size of packets of new bone. DESIGN AND MEASUREMENTS: The width of packets of cancellous bone (wall width) was measured at random intercepts and mean values calculated. Cancellous bone area and perimeter were also measured. Indices of trabecular separation and the complementary quantity trabecular number were derived according to Parfitt's method, as well as trabecular width. Patients were used as their own controls and changes in these indices calculated. Correlations were calculated for data obtained from independent measurements. PATIENTS: We studied eleven women with post-menopausal osteoporosis, diagnosed by fractures after exclusion of causes of secondary osteoporosis.
RESULTS: One woman did not comply with her HRT therapy. In the others, treatment with hPTH 1-34 + HRT restored the characteristically depressed pre-treatment values of wall width to normal. Trabecular width increased approximately four times more than wall width. Changes in wall width correlated with changes in cancellous bone area; however, bone area increased considerably more than could be accounted for statistically by changes in wall width. A decrease in trabecular separation was found to account for the additional increase in bone area (P = 0.056).
CONCLUSION: hPTH 1-34 + oestrogen and progestagen therapy increases the width of packets of new cancellous bone with consequent increases in the width of trabecular plates.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1424211     DOI: 10.1111/j.1365-2265.1992.tb02323.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  12 in total

1.  Parathyroid hormone treatment improves the cortical bone microstructure by improving the distribution of type I collagen in postmenopausal women with osteoporosis.

Authors:  Maria-Grazia Ascenzi; Vivian P Liao; Brittany M Lee; Fabrizio Billi; Hua Zhou; Robert Lindsay; Felicia Cosman; Jeri Nieves; John P Bilezikian; David W Dempster
Journal:  J Bone Miner Res       Date:  2012-03       Impact factor: 6.741

Review 2.  Parathyroid hormone for the treatment of osteoporosis: a systematic review.

Authors:  Ann Cranney; Alexandra Papaioannou; Nicole Zytaruk; David Hanley; Jonathan Adachi; David Goltzman; Timothy Murray; Anthony Hodsman
Journal:  CMAJ       Date:  2006-07-04       Impact factor: 8.262

Review 3.  The bone-building action of the parathyroid hormone: implications for the treatment of osteoporosis.

Authors:  J F Whitfield; P Morley; G E Willick
Journal:  Drugs Aging       Date:  1999-08       Impact factor: 3.923

Review 4.  Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size.

Authors:  David B Burr
Journal:  Curr Osteoporos Rep       Date:  2005-03       Impact factor: 5.096

5.  Effects of reciprocal treatment with estrogen and estrogen plus parathyroid hormone on bone structure and strength in ovariectomized rats.

Authors:  V Shen; R Birchman; R Xu; M Otter; D Wu; R Lindsay; D W Dempster
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

6.  Increased cancellous bone in the femoral neck of patients with coxarthrosis (hip osteoarthritis): a positive remodeling imbalance favoring bone formation.

Authors:  G R Jordan; N Loveridge; J Power; M T Clarke; J Reeve
Journal:  Osteoporos Int       Date:  2003-03-05       Impact factor: 4.507

7.  Stimulation of creatine kinase activity in rat skeletal tissue in vivo and in vitro by protease-resistant variants of parathyroid hormone fragments.

Authors:  D Sömjen; V Vargas; A Waisman; E Wingender; W Tegge; A M Kaye
Journal:  Biochem J       Date:  1995-07-01       Impact factor: 3.857

8.  Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis.

Authors:  R Lindsay; P Miller; G Pohl; E V Glass; P Chen; J H Krege
Journal:  Osteoporos Int       Date:  2008-10-16       Impact factor: 4.507

9.  Expression of Rho GDIalpha in rat osteoblasts intermittently exposed to parathyroid hormone in vitro and in vivo.

Authors:  Zu-Feng Sun; Hui Jiang; Zheng-Qin Ye; Bing Jia; Xiao-le Zhang; Ke-Qin Zhang
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

Review 10.  Bone physiology, disease and treatment: towards disease system analysis in osteoporosis.

Authors:  Teun M Post; Serge C L M Cremers; Thomas Kerbusch; Meindert Danhof
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.